Manjyot K Nanhwan1, Shukuan Ling1, Monica Kodakandla1, Sven Nylander1, Yumei Ye1, Yochai Birnbaum2. 1. From the Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston (M.K.N., S.L., M.K., Y.Y., Y.B.); State Key Laboratory of Space Medicine Fundamentals and Application, China Astronaut Research and Training Center, Beijing, China (S.L.); AstraZeneca R&D, Mölndal, Sweden (S.N.); and Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX (Y.B.). 2. From the Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston (M.K.N., S.L., M.K., Y.Y., Y.B.); State Key Laboratory of Space Medicine Fundamentals and Application, China Astronaut Research and Training Center, Beijing, China (S.L.); AstraZeneca R&D, Mölndal, Sweden (S.N.); and Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX (Y.B.). ybirnbau@bcm.edu.
Abstract
OBJECTIVE: In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in patients with acute coronary syndromes. In addition to P2Y12-receptor antagonism, ticagrelor prevents cell uptake of adenosine and has proven able to augment adenosine effects. Adenosine protects the heart against ischemia-reperfusion injury. We compared the effects of clopidogrel and ticagrelor on myocardial infarct size (IS). APPROACH AND RESULTS: Rats received oral ticagrelor (0, 75, 150, or 300 mg/kg/d) or clopidogrel (30 or 90 mg/kg/d) for 7 days and underwent 30-minute coronary artery ligation and 24-hour reperfusion. Area at risk was assessed by blue dye and IS by 2,3,5-triphenyl-tetrazolium-chloride. Cyclooxygenase-2 (COX2) enzyme activity was assessed by ELISA and expression by real-time polymerase chain reaction. Mechanism responsible was explored using adenosine-receptor antagonist (CGS15943, an A2A/A1 antagonist) or cyclooxygenase inhibition by either aspirin (5, 10, or 25 mg/kg) or specific cyclooxygenase-1 (SC560) or COX2 (SC5815) inhibitors. Ticagrelor, dose-dependently, reduced IS, whereas clopidogrel had no effect. Adenosine-receptor antagonism blocked the ticagrelor effect and COX2 inhibition by SC5815, or high-dose aspirin attenuated the IS-limiting effect of ticagrelor, whereas cyclooxygenase-1 inhibition or low-dose aspirin had no effect. Ticagrelor, but not clopidogrel, upregulated COX2 expression and activity. Also this effect was blocked by adenosine-receptor antagonism. Ticagrelor, but not clopidogrel, increased Akt and endothelial nitric oxide synthase phosphorylation. CONCLUSIONS: Ticagrelor, but not clopidogrel, reduces myocardial IS. The protective effect of ticagrelor was dependent on adenosine-receptor activation with downstream upregulation of endothelial nitric oxide synthase and COX2 activity.
OBJECTIVE: In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in patients with acute coronary syndromes. In addition to P2Y12-receptor antagonism, ticagrelor prevents cell uptake of adenosine and has proven able to augment adenosine effects. Adenosine protects the heart against ischemia-reperfusion injury. We compared the effects of clopidogrel and ticagrelor on myocardial infarct size (IS). APPROACH AND RESULTS:Rats received oral ticagrelor (0, 75, 150, or 300 mg/kg/d) or clopidogrel (30 or 90 mg/kg/d) for 7 days and underwent 30-minute coronary artery ligation and 24-hour reperfusion. Area at risk was assessed by blue dye and IS by 2,3,5-triphenyl-tetrazolium-chloride. Cyclooxygenase-2 (COX2) enzyme activity was assessed by ELISA and expression by real-time polymerase chain reaction. Mechanism responsible was explored using adenosine-receptor antagonist (CGS15943, an A2A/A1 antagonist) or cyclooxygenase inhibition by either aspirin (5, 10, or 25 mg/kg) or specific cyclooxygenase-1 (SC560) or COX2 (SC5815) inhibitors. Ticagrelor, dose-dependently, reduced IS, whereas clopidogrel had no effect. Adenosine-receptor antagonism blocked the ticagrelor effect and COX2 inhibition by SC5815, or high-dose aspirin attenuated the IS-limiting effect of ticagrelor, whereas cyclooxygenase-1 inhibition or low-dose aspirin had no effect. Ticagrelor, but not clopidogrel, upregulated COX2 expression and activity. Also this effect was blocked by adenosine-receptor antagonism. Ticagrelor, but not clopidogrel, increased Akt and endothelial nitric oxide synthase phosphorylation. CONCLUSIONS:Ticagrelor, but not clopidogrel, reduces myocardial IS. The protective effect of ticagrelor was dependent on adenosine-receptor activation with downstream upregulation of endothelial nitric oxide synthase and COX2 activity.
Authors: Heerajnarain Bulluck; Mervyn H H Chan; Jennifer A Bryant; Ping Chai; Ashish Chawla; Terrance S Chua; Yiu-Cho Chung; Gao Fei; Hee H Ho; Andrew F W Ho; Andrew J Hoe; Syed S Imran; Chi-Hang Lee; Swee H Lim; Boon W Liew; Patrick L Z Yun; Marcus O E Hock; Valeria Paradies; Matthew T Roe; Lynette Teo; Aaron S Wong; Evelyn Wong; Philip E Wong; Timothy Watson; Mark Y Chan; Jack W Tan; Derek J Hausenloy Journal: Clin Cardiol Date: 2018-12-17 Impact factor: 2.882
Authors: Regina Ye; Hani Jneid; Mahboob Alam; Barry F Uretsky; Dan Atar; Masafumi Kitakaze; Sean M Davidson; Derek M Yellon; Yochai Birnbaum Journal: Cardiovasc Drugs Ther Date: 2022-02-16 Impact factor: 3.727
Authors: Mohammed Ahmed Akkaif; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Nur Aizati Athirah Daud; Abubakar Sha'aban; Baharudin Ibrahim Journal: Pharmacol Rep Date: 2021-07-20 Impact factor: 3.024
Authors: Karla N Samman; Pamela Mehanna; Emad Takla; Jean-Christophe Grenier; Mark Y Chan; Renato D Lopes; Megan Lee Neely; Tracy Y Wang; L Kristin Newby; Richard C Becker; Marie Lordkipanidzé; Matthieu Ruiz; Julie G Hussin; E Marc Jolicœur Journal: Cell Rep Med Date: 2021-06-04